Drug
Goserelin clinical trials
Also written Zoladex and ICI-118630.
- studies test it
- 102
- open now
- 17
- in phase 3
- 33
- first study started
- 1990
Keep track of what changes. Save the Goserelin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Zoladex
- 46
Development codes
Studies by the year they started
98 studies that test it; most in 2006 (9)
| Year | Studies |
|---|---|
| 1990 | 1 |
| 1994 | 1 |
| 1995 | 1 |
| 1997 | 1 |
| 1999 | 2 |
| 2000 | 4 |
| 2001 | 2 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 9 |
| 2007 | 5 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 6 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 4 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 6
- Phase 2
- 39
- Phase 3
- 33
- Phase 4
- 13
- No phase
- 13
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 88
AstraZeneca (7) · Fudan University (4) · Radiation Therapy Oncology Group (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · City of Hope Medical Center (2) · Stanford University (2) · Eurofarma Laboratorios S.A. (2) · Novartis Pharmaceuticals (2)
Often tested with
Tested in the same studies.
Leuprolide (16) · Bicalutamide (15) · Letrozole (9) · Anastrozole (7) · Degarelix (6) · Flutamide (6) · Triptorelin (6) · Fulvestrant (6)
Studies
Open first, then newest update. How each study uses Goserelin is read from its arms, and is right about nine times in ten.
Testing it · 102
- A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast CancerRecruitingPhase 1TerSera Therapeutics LLCNCT07310420Written as ZOLADEX
- Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer PatientsRecruitingPhase 2Mayo ClinicNCT07460752Written as Goserelin Acetate
- ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)Not yet recruitingPhase 3Dr. Tamim NiaziNCT07777263Written as ZOLADEX 10.8 mg
- Adaptions and Resiliency to Multi-Stressor OpeRationsRecruitingPhase 4Bradley NindlNCT06455969Written as Goserelin 3.6 MG
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreRecruitingPhase 2Washington University School of MedicineNCT02476786Written as Goserelin
- Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT07158021Written as Goserelin
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as Goserelin
- Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using GoserelinNot yet recruitingNot applicableUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07552480Written as Goserelin
- Clinical Study on the Preservation of Ovarian Function Following Autologous Hematopoietic Stem Cell Transplantation Using GoserelinNot yet recruitingNot applicableUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07552493Written as Goserelin 3.6 MG
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular TracersRecruitingPhase 2/3Cancer Research AntwerpNCT06282588Written as Zoladex 3.6Mg Implant
- Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryRecruitingPhase 2University of ChicagoNCT06348134Written as Goserelin
- Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer PatientsRecruitingPhase 2National Taiwan University HospitalNCT06225284Written as Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingPhase 2Fudan UniversityNCT05594095Written as Goserelin
- To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate CancerRecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06385847Written as Zoladex
- Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma PatientsEnrolling by invitationPhase 2Beni-Suef UniversityNCT04536467Written as Goserelin
- Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624RecruitingPhase 3Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología RadioterápicNCT05781217Written as triptorelin, goserelin, leuprorelin
- To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or MifepristoneNot yet recruitingNot applicableWomen's Hospital School Of Medicine Zhejiang UniversityNCT05898321Written as Zoladex
- Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate CancerActive, not recruitingPhase 1/2German Oncology Center, CyprusNCT05003752Written as Goserelin 10.8 mg
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialActive, not recruitingPhase 3NRG OncologyNCT05050084Written as Goserelin
- Effect of a GnRH Analog on Hepatic SteatosisActive, not recruitingPhase 4Aristotle University Of ThessalonikiNCT06523530Written as Goserelin Acetate 3.6 mg inj, implant
See all 102 studies that test Goserelin →
Given in every arm · 97 — Goserelin is usual care beside what is tested
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT03678025Written as Goserelin Acetate
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerRecruitingPhase 2Eli Lilly and CompanyNCT07287098Written as Goserelin
- QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07782840Written as Ovarian function suppression
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET ImagingRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT04423211Written as Goserelin Acetate
- Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine TherapyRecruitingPhase 2Yale UniversityNCT06953882Written as Goserelin 3.6 MG
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerRecruitingPhase 2City of Hope Medical CenterNCT04734730Written as Goserelin Acetate
- Phase II Dutasteride in Combination With CAB vs CAB in SDCRecruitingPhase 2Radboud University Medical CenterNCT05513365Written as Goserelin 10.8 mg
- Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate CancerRecruitingPhase 2Xijing HospitalNCT06575257Written as Goserelin 3.6 mg
- Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCRecruitingPhase 2National Taiwan University HospitalNCT05720260Written as Goserelin
- Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young WomenRecruitingPhase 3First Affiliated Hospital, Sun Yat-Sen UniversityNCT02914158Written as Goserelin
- Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate CancerRecruitingNot applicableNational Taiwan University HospitalNCT04894188Written as Goserelin 3.6 MG
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerActive, not recruitingPhase 3SWOG Cancer Research NetworkNCT01674140Written as goserelin acetate
- Phase IIIb Study of Ribociclib + ET in Early Breast CancerActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05827081Written as Goserelin
- Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02115282Written as Goserelin
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerActive, not recruitingPhase 2/3VA Office of Research and DevelopmentNCT04787744Written as Goserelin, Histrelin, Leuprolide & Triptorelin
- Roll-over Study to Allow Continued Access to RibociclibActive, not recruitingPhase 4Novartis PharmaceuticalsNCT05161195Written as Goserelin
- Neo-DAB: Darolutamide and Abemaciclib in Prostate CancerTerminatedPhase 1Praful Ravi, MB BCHir, MRCPNCT05617885Written as GNRH-A Goserelin
- Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerCompletedPhase 3National Cancer Institute (NCI)NCT02003209Written as Goserelin Acetate
- PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast CancerActive, not recruitingPhase 2Washington University School of MedicineNCT01723774Written as Goserelin
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by SurgeryActive, not recruitingPhase 2/3NRG OncologyNCT03070886Written as Goserelin
Showing 20 of 97.
As the comparator · 23 — what is tested is compared with Goserelin
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialRecruitingPhase 2Mayo ClinicNCT06378866Written as Goserelin
- Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RPRecruitingPhase 2Cancer Research AntwerpNCT03899077Written as Goserelin Acetate 10.8 MG Subcutaneous Implant
- Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mgNot yet recruitingPhase 1Luye Pharma Group Ltd.NCT05856630Written as Zoladex 10.8 MG Drug Implant
- Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate CancerCompletedPhase 2University of Colorado, DenverNCT02278185Written as goserelin acetate
- A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate CancerCompletedPhase 3Astellas Pharma IncNCT01964170Written as Goserelin
- Study of Histrelin Subdermal Implant in Patients With Prostate CancerCompletedPhase 3Endo PharmaceuticalsNCT01394263Written as Zoladex goserelin implant
- Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®CompletedPhase 1Luye Pharma Group Ltd.NCT05140512Written as ZOLADEX® 3.6 mg
- Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®CompletedPhase 3Luye Pharma Group Ltd.NCT05110170Written as ZOLADEX® 3.6 mg
- Study to Compare the Bioavailability, Safety and Tolerability of XM17 in Healthy, Down Regulated Young WomenCompletedPhase 1Merckle GmbHNCT02592031Written as Zoladex®
- International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate CancerCompletedPhase 2Spectrum Pharmaceuticals, IncNCT01252693Written as Goserelin
- Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®CompletedPhase 3Luye Pharma Group Ltd.NCT04563936Written as ZOLADEX® 3.6 mg
- Prostate Adenocarcinoma TransCutaneous HormonesStatus unknownPhase 3University College, LondonNCT00303784Written as Goserelin
- A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate CancerCompletedPhase 1Luye Pharma Group Ltd.NCT03450109Written as Zoladex
- Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate CancerCompletedPhase 2SOTIO a.s.NCT02107391Written as Goserelin Acetate
- Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate CancerTerminatedPhase 4PharmatechNCT02749825Written as Zoladex
- One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese PopulationCompletedPhase 3Ferring PharmaceuticalsNCT01744366Written as Goserelin
- A Degarelix Trial in Patients With Prostate CancerTerminatedPhase 3Ferring PharmaceuticalsNCT01242748Written as Goserelin acetate
- A Trial of Degarelix in Patients With Prostate CancerCompletedPhase 3Ferring PharmaceuticalsNCT00946920Written as Goserelin acetate
- Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer PatientsCompletedPhase 3Ferring PharmaceuticalsNCT00884273Written as Goserelin
- Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate CancerTerminatedPhase 3Ferring PharmaceuticalsNCT00831233Written as Goserelin
Showing 20 of 23.
Codes
What other systems call Goserelin · ClinicalTrials.gg INT008568
- MeSH (NLM) D017273GoserelinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 0F65R8P09NGOSERELINConfirmed FDA, NLM, Wikidata
- RxNorm 50610Confirmed FDA, Wikidata
- Wikidata Q1992653goserelinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1374GoserelinOne source FDA
- DrugBank DB00014One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D017273 | Goserelin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 0F65R8P09N | GOSERELIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 50610 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1992653 | goserelin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1374 | Goserelin | One source FDA |
| DrugBank | DB00014 | — | One source Wikidata |
Also registered as goserelin acetate (UNII 6YUU2PV0U8 · RxNorm 203146).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.